ROADMAP aims to create the conditions for an open collaboration that yields consensual and efficient uses of RWE for the benefit of Alzheimer’s Disease patients and their caregivers. This will be achieved by 1) using pilot studies to assess methods of data integration for patient outcomes that are useful for disease modelling; and 2) developing tools and methods for stakeholder engagement. ROADMAP will set new standards for the collation and evaluation of RWE in Alzheimer’s Disease.
ROADMAP has an initial duration of 2 years with an indicative budget of €7.7M distributed across a total of 22 partners from the private and academic sectors. The project has been sponsored mainly by the European Union’s Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking